Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial

To investigate the safety and efficacy of nivolumab plus cabozantinib with or without ipilimumab in patients with advanced hepatocellular carcinoma. METHODS: In cohort 6 of the multicohort, open-label, phase I/II CheckMate 040 study, patients who were treatment-naive, sorafenib-intolerant, or had pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yau, Thomas, Zagonel, Vittorina, Santoro, Armando, Acosta-Rivera, Mirelis, Choo, Su Pin, Matilla, Ana, He, Aiwu Ruth, Cubillo Gracian, Antonio, El-Khoueiry, Anthony B., Sangro, Bruno, Eldawy, Tarek E., Bruix, Jordi, Frassineti, Giovanni Luca, Vaccaro, Gina M., Tschaika, Marina, Scheffold, Christian, Koopmans, Petra, Neely, Jaclyn, Piscaglia, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022845/
https://www.ncbi.nlm.nih.gov/pubmed/36512738
http://dx.doi.org/10.1200/JCO.22.00972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022845/
https://www.ncbi.nlm.nih.gov/pubmed/36512738
http://dx.doi.org/10.1200/JCO.22.00972

Ejemplares similares